KYTX
Kyverna Therapeutics, Inc.
Biotechnology
Market Cap$407M
5Y Perf.-65.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
KYTX vs CABA
Revenue, margins, valuation, and 5-year total return — side by side.
CABA
Cabaletta Bio, Inc.
Biotechnology
Market Cap$409M
5Y Perf.-82.5%
KYTX vs CABA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KYTX | CABA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $407M | $409M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-161M | $-168M |
| Total Debt | $8M | $27M |
| Cash & Equiv. | $97M | $83M |
KYTX vs CABA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KYTX
CABA
| Stock | Feb 24 | May 26 | Return |
|---|---|---|---|
| Kyverna Therapeutic… (KYTX) | 100 | 34.2 | -65.8% |
| Cabaletta Bio, Inc. (CABA) | 100 | 17.5 | -82.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KYTX vs CABA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KYTX and CABA are tied at the top with 2 categories each — the right choice depends on your priorities. Cabaletta Bio, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
KYTX
Kyverna Therapeutics, Inc.
The Defensive Pick
KYTX has the current edge in this matchup, primarily because of its strength in sleep-well-at-night.
- Lower volatility, beta 3.05, Low D/E 3.1%, current ratio 8.61x
- +360.4% vs CABA's +244.8%
- -86.0% ROA vs CABA's -90.2%, ROIC -106.0% vs -429.6%
Best for: sleep-well-at-night
CABA
Cabaletta Bio, Inc.
The Income Pick
CABA is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 1 yrs, beta 2.54
- EPS growth 29.9%
- -60.0% 10Y total return vs KYTX's -69.0%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CABA | -47.0% revenue growth vs KYTX's -91.8% |
| Stability / Safety | CABA | Beta 2.54 vs KYTX's 3.05 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | KYTX | +360.4% vs CABA's +244.8% |
| Efficiency (ROA) | KYTX | -86.0% ROA vs CABA's -90.2%, ROIC -106.0% vs -429.6% |
KYTX vs CABA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCABALAGGINGKYTX
KYTXKyverna Therapeutics,…
2leads
CABACabaletta Bio, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs KYTXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CABA1/1
Valuation MetricsMultiples, price ratios, and targets
KYTX2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KYTX8/8
Total Returns1Y, 3Y, 5Y total returns with dividends
CABA5/6
Risk & VolatilityBeta, volatility, and downside exposure
CABA2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CABA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
KYTX and CABA operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | KYTXKyverna Therapeut… | CABACabaletta Bio, In… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$170M | -$172M |
| Net IncomeAfter-tax profit | -$161M | -$168M |
| Free Cash FlowCash after capex | -$158M | -$132M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -6.3% | +36.9% |
CABA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
KYTX leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | KYTXKyverna Therapeut… | CABACabaletta Bio, In… |
|---|---|---|
| Market CapShares × price | $407M | $409M |
| Enterprise ValueMkt cap + debt − cash | $319M | $353M |
| Trailing P/EPrice ÷ TTM EPS | -2.79x | -2.44x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 1.34x | 3.65x |
| Price / FCFMarket cap ÷ FCF | — | — |
KYTX leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
KYTX leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
KYTX delivers a -106.0% return on equity — every $100 of shareholder capital generates $-106 in annual profit, vs $-122 for CABA. KYTX carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to CABA's 0.24x. On the Piotroski fundamental quality scale (0–9), KYTX scores 5/9 vs CABA's 1/9, reflecting solid financial health.
| Metric | KYTXKyverna Therapeut… | CABACabaletta Bio, In… |
|---|---|---|
| ROE (TTM)Return on equity | -106.0% | -121.7% |
| ROA (TTM)Return on assets | -86.0% | -90.2% |
| ROICReturn on invested capital | -106.0% | -4.3% |
| ROCEReturn on capital employed | -87.4% | -126.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 1 |
| Debt / EquityFinancial leverage | 0.03x | 0.24x |
| Net DebtTotal debt minus cash | -$88M | -$56M |
| Cash & Equiv.Liquid assets | $97M | $83M |
| Total DebtShort + long-term debt | $8M | $27M |
| Interest CoverageEBIT ÷ Interest expense | -2204.37x | — |
KYTX leads this category, winning 8 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
CABA leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CABA five years ago would be worth $4,180 today (with dividends reinvested), compared to $3,100 for KYTX. Over the past 12 months, KYTX leads with a +360.4% total return vs CABA's +244.8%. The 3-year compound annual growth rate (CAGR) favors CABA at -30.1% vs KYTX's -32.3% — a key indicator of consistent wealth creation.
| Metric | KYTXKyverna Therapeut… | CABACabaletta Bio, In… |
|---|---|---|
| YTD ReturnYear-to-date | +6.0% | +81.0% |
| 1-Year ReturnPast 12 months | +360.4% | +244.8% |
| 3-Year ReturnCumulative with dividends | -69.0% | -65.8% |
| 5-Year ReturnCumulative with dividends | -69.0% | -58.2% |
| 10-Year ReturnCumulative with dividends | -69.0% | -60.0% |
| CAGR (3Y)Annualised 3-year return | -32.3% | -30.1% |
CABA leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
CABA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CABA is the less volatile stock with a 2.54 beta — it tends to amplify market swings less than KYTX's 3.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CABA currently trades 94.6% from its 52-week high vs KYTX's 68.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KYTXKyverna Therapeut… | CABACabaletta Bio, In… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.05x | 2.54x |
| 52-Week HighHighest price in past year | $13.67 | $4.23 |
| 52-Week LowLowest price in past year | $1.95 | $1.11 |
| % of 52W HighCurrent price vs 52-week peak | +68.0% | +94.6% |
| RSI (14)Momentum oscillator 0–100 | 54.2 | 60.8 |
| Avg Volume (50D)Average daily shares traded | 869K | 2.8M |
CABA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates KYTX as "Buy" and CABA as "Buy". Consensus price targets imply 308.2% upside for CABA (target: $16) vs 251.3% for KYTX (target: $33).
| Metric | KYTXKyverna Therapeut… | CABACabaletta Bio, In… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $32.67 | $16.33 |
| # AnalystsCovering analysts | 4 | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% |
Insufficient data to determine a leader in this category.
Key Takeaway
CABA leads in 3 of 6 categories (Income & Cash Flow, Total Returns). KYTX leads in 2 (Valuation Metrics, Profitability & Efficiency).
Best OverallCabaletta Bio, Inc. (CABA)Leads 3 of 6 categories
Loading custom metrics...
KYTX vs CABA: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is KYTX or CABA a better buy right now?
Analysts rate Kyverna Therapeutics, Inc.
(KYTX) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KYTX or CABA?
Over the past 5 years, Cabaletta Bio, Inc.
(CABA) delivered a total return of -58. 2%, compared to -69. 0% for Kyverna Therapeutics, Inc. (KYTX). Over 10 years, the gap is even starker: CABA returned -60. 0% versus KYTX's -69. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KYTX or CABA?
By beta (market sensitivity over 5 years), Cabaletta Bio, Inc.
(CABA) is the lower-risk stock at 2. 54β versus Kyverna Therapeutics, Inc. 's 3. 05β — meaning KYTX is approximately 20% more volatile than CABA relative to the S&P 500. On balance sheet safety, Kyverna Therapeutics, Inc. (KYTX) carries a lower debt/equity ratio of 3% versus 24% for Cabaletta Bio, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — KYTX or CABA?
Kyverna Therapeutics, Inc.
(KYTX) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Cabaletta Bio, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KYTX leads at 0. 0% versus 0. 0% for CABA. At the gross margin level — before operating expenses — KYTX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — KYTX or CABA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is KYTX or CABA better for a retirement portfolio?
For long-horizon retirement investors, Cabaletta Bio, Inc.
(CABA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Kyverna Therapeutics, Inc. (KYTX) carries a higher beta of 3. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CABA: -60. 0%, KYTX: -69. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between KYTX and CABA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.